blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2385145

EP2385145 - Compostions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.08.2019
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  07.09.2018
FormerGrant of patent is intended
Status updated on  30.05.2018
FormerExamination is in progress
Status updated on  24.02.2017
Most recent event   Tooltip16.07.2021Lapse of the patent in a contracting state
New state(s): HU		published on 18.08.2021  [2021/33]
Applicant(s)For all designated states
Monogram BioSciences, Inc.
345 Oyster Point Boulevard
South San Francisco, CA 94080 / US
[2018/41]
Former [2011/45]For all designated states
Monogram BioSciences, Inc.
345 Oyster Point Boulevard
South San Francisco, CA 94080 / US
Inventor(s)01 / Petropoulos, Christos
415 Garcia Drive
Half Moon Bay, CA 94109 / US
 [2011/45]
Representative(s)Donald, Jenny Susan
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
[2018/41]
Former [2011/45]Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11
80538 München / DE
Application number, filing date11161793.207.06.2005
[2011/45]
Priority number, dateUS20040577851P07.06.2004         Original published format: US 577851 P
[2011/45]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2385145
Date:09.11.2011
Language:EN
[2011/45]
Type: A3 Search report 
No.:EP2385145
Date:25.11.2015
Language:EN
[2015/48]
Type: B1 Patent specification 
No.:EP2385145
Date:10.10.2018
Language:EN
[2018/41]
Search report(s)(Supplementary) European search report - dispatched on:EP23.10.2015
ClassificationIPC:C12Q1/70, C12N7/00, G01N33/50, C12Q1/66, C07K14/005, C12Q1/04
[2015/48]
CPC:
C12Q1/703 (EP,US); C07K14/005 (EP,US); C12N7/00 (EP,US);
C12Q1/04 (EP,US); C12Q1/66 (EP,US); C12Q1/70 (US);
G01N33/5008 (EP,US); C12N2740/16021 (US); C12N2740/16062 (EP,US);
C12N2740/16122 (EP,US); C12N2770/20021 (US); C12N2800/107 (EP,US);
C12N2800/40 (EP,US); G01N2333/16 (EP,US); G01N2333/162 (EP,US) (-)
Former IPC [2015/13]C12Q1/70, C12N7/00, G01N33/50, C12Q1/66, C07K14/005
Former IPC [2011/45]C12Q1/70, C12N7/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/27]
Former [2011/45]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL25.05.2016
BA25.05.2016
HR25.05.2016
LV25.05.2016
MK25.05.2016
YU25.05.2016
TitleGerman:Zusammensetzungen und Verfahren zur Bestimmung der Resistenz gegen Vireneintrittshemmer mit rekombinanten Virenassays[2011/45]
English:Compostions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays[2011/45]
French:Compositions et procédés permettant de déterminer la résistance des inhibiteurs à la saisie de virus à l'aide d'analyses de virus recombinants[2011/45]
Examination procedure25.05.2016Examination requested  [2016/27]
01.07.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
12.09.2016Amendment by applicant (claims and/or description)
22.02.2017Despatch of a communication from the examining division (Time limit: M06)
04.09.2017Reply to a communication from the examining division
15.11.2017Despatch of a communication from the examining division (Time limit: M04)
23.03.2018Reply to a communication from the examining division
31.05.2018Communication of intention to grant the patent
31.08.2018Fee for grant paid
31.08.2018Fee for publishing/printing paid
31.08.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP05791148.9  / EP1774049
Divisional application(s)EP18199100.1  / EP3483289
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20050791148) is  09.04.2009
Opposition(s)11.07.2019No opposition filed within time limit [2019/38]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
12.09.2016Request for further processing filed
12.09.2016Full payment received (date of receipt of payment)
Request granted
28.09.2016Decision despatched
Fees paidRenewal fee
06.06.2011Renewal fee patent year 03
06.06.2011Renewal fee patent year 04
06.06.2011Renewal fee patent year 05
06.06.2011Renewal fee patent year 06
06.06.2011Renewal fee patent year 07
14.06.2012Renewal fee patent year 08
10.06.2013Renewal fee patent year 09
12.06.2014Renewal fee patent year 10
10.06.2015Renewal fee patent year 11
10.06.2016Renewal fee patent year 12
16.06.2017Renewal fee patent year 13
10.08.2018Renewal fee patent year 14
Penalty fee
Additional fee for renewal fee
30.06.201814   M06   Fee paid on   10.08.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.06.2005
AT10.10.2018
CY10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
TR10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
IE07.06.2019
LU07.06.2019
CH30.06.2019
LI30.06.2019
[2021/33]
Former [2021/26]AT10.10.2018
CY10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
TR10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
IE07.06.2019
LU07.06.2019
CH30.06.2019
LI30.06.2019
Former [2020/25]AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
TR10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
IE07.06.2019
LU07.06.2019
CH30.06.2019
LI30.06.2019
Former [2020/21]AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
TR10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
IE07.06.2019
Former [2020/17]AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
TR10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2020/08]AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/50]AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/40]AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
SE10.10.2018
SK10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/37]AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
SE10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/35]AT10.10.2018
CZ10.10.2018
DK10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
NL10.10.2018
PL10.10.2018
SE10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/34]AT10.10.2018
DK10.10.2018
ES10.10.2018
FI10.10.2018
IT10.10.2018
LT10.10.2018
NL10.10.2018
PL10.10.2018
SE10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/26]AT10.10.2018
ES10.10.2018
FI10.10.2018
LT10.10.2018
NL10.10.2018
PL10.10.2018
SE10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/24]AT10.10.2018
ES10.10.2018
FI10.10.2018
LT10.10.2018
NL10.10.2018
PL10.10.2018
SE10.10.2018
BG10.01.2019
GR11.01.2019
IS10.02.2019
Former [2019/23]AT10.10.2018
ES10.10.2018
FI10.10.2018
LT10.10.2018
NL10.10.2018
PL10.10.2018
BG10.01.2019
IS10.02.2019
Former [2019/22]FI10.10.2018
LT10.10.2018
NL10.10.2018
PL10.10.2018
BG10.01.2019
IS10.02.2019
Former [2019/21]FI10.10.2018
LT10.10.2018
NL10.10.2018
IS10.02.2019
Former [2019/20]LT10.10.2018
NL10.10.2018
Former [2019/17]NL10.10.2018
Documents cited:Search[I]US5837464  (CAPON DANIEL [US], et al) [I] 14-25 * col 1, l 10-16 ; col 10, l 23-54;; figures 2-8 *;
 [I]US2002037500  (WHITCOMB JEANNETTE [US]) [I] 14-25 * paragraphs [0064] - [0068] - [0134]; figures 1-4,6-10,12-,15,18-19; example 1; claim 5 *;
 [X]US2002182592  (PETROPOULOS CHRISTOS J [US], et al) [X] 1-13 * paragraphs [0074] , [0 82] - [0087] - [ 146] - [0147] - [ 166]; figures 4b, 11-12; examples 1,7; claims 1-13, 21, 34, 37 *;
 [X]WO03070985  (VIROLOGIC INC [US], et al) [X] 1-25 * pg 28, l 16 - pg 29, l 1 ; pg 31, l 33ff ; pg 32, l 33 - pg 33, l 13 ; pg 34, l 1-3 ; page 61-62 ; pg 33, l 31-34 ; pg 34, l 12-15 ; pg 55, l 19-29 ; figs 4-5,7-8 ; example 8-9;; figures 1a,1b1 4a; table 4 *;
 [A]  - Q.-X. HU ET AL, "Evolution of the Human Immunodeficiency Virus Type 1 Envelope during Infection Reveals Molecular Corollaries of Specificity for Coreceptor Utilization and AIDS Pathogenesis", JOURNAL OF VIROLOGY, (20001215), vol. 74, no. 24, doi:10.1128/JVI.74.24.11858-11872.2000, ISSN 0022-538X, pages 11858 - 11872, XP055168702 [A] 1-13 * pg 11860, col 2, para "production of pseudotyped reporter viruses.." ; pg 11859, col 2, para bridging pg 11860 ;;; figures 2-4; table 2 *

DOI:   http://dx.doi.org/10.1128/JVI.74.24.11858-11872.2000
 [XI]  - SI Z ET AL, "Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 101, no. 14, doi:10.1073 PNAS.0307953101, ISSN 0027-8424, (20040406), pages 5036 - 5041, (20040329), XP009166820 [X] 1,3,4,7-11,13 * pg 5036, col 2, para bridging pg 5037 ;;; figures 1-2 * [I] 2,5,6,12

DOI:   http://dx.doi.org/10.1073 pnas.0307953101
    [ ] - Z Si ET AL, "SuppText: Small-molecule inhibitors of HIV-1 entry block receptor- induced conformational changes in the viral envelope glycoprotein", PNAS, (20040406), pages 1 - 2, URL: http://www.pnas.org/content/suppl/2004/03/17/0307953101.DC1/07953SuppText.html, (20150211), XP055169026 [ ] * para "plasmids" ; para "HIV-1 infectivity assay" ; *
 [XI]  - WEI XIPING ET AL, "Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (200206), vol. 46, no. 6, ISSN 0066-4804, pages 1896 - 1905, XP008055247 [X] 1-11,13 * page 6, l 34 - pg 8, l 31 ;; page 1897, column 2, paragraphs PHENOTYPIC,ANALYSIS,OF,T-20,ENV,SENSITIVITY; figures 4-5, 1a, 1b, 2-3; tables 1, 3 * [I] 12

DOI:   http://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002
 [A]  - P Sista ET AL, "subgroup analysis of baseline (BL) susce ptibility and early virological response to Enfuvirtide in the combined TORO studies", XII International HIV Drug Resistan ce Workshop, Cabo Del Sol, Los Cabos, Mexico, June 10-14, 200, (20030610), page poster 55, URL: http://medadvocates.org/resources/conferences/intdrugresistworkshop/12intdrugresistanceworkshop/final%20sista%20poster%20subgroup%20analysis.pdf, (20151006), XP055218603 [A] 14-25 * column 2, paragraph 3 *
 [A]  - ANGARANO G ET AL, "Genotype and phenotype resistance: an overview", JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, WICHTIG EDITORE, MILAN, IT, (20000101), vol. 14, no. 1, ISSN 0393-974X, pages 11 - 14, XP008098835 [A] 14-25 * table 1 *
by applicantWO9727319
 US5837464
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 10
    - ALTSCHUL ET AL., NUCLEIC ACIDS RES., (1997), vol. 25, pages 3389 - 3402
    - EISENBERG ET AL., J MOL. BIOL., (1984), vol. 179, pages 125 - 142
    - EISENBERG ET AL., J. MOL. BIOL., (1984), vol. 179, pages 125 - 142
    - MAXAM ET AL., METHODS IN ENZYMOLOGY, (1980), vol. 65, page 499
    - SANGER ET AL., PROC. NATL. ACAD SCI. USA, (1977), vol. 74, page 5463
    - BARNES, W.M., PROC. NATL. ACAD. SCI, USA, (1994), vol. 91, pages 2216 - 2220
    - ADACHI, A., H. E. GENDELMAN, S. KOENIG, T. FOLKS, R. CANEY, A. RABSON, M. A. MARTIN, "Production of Acquired Immunodeficiency Syndrome-associated Retrovirus in Human and Nonhuman Cells Transfected with an Infectious Molecular Clone", J. VIROL., (1986), vol. 59, pages 284 - 291
    - ALKHATIB, G., C. COMBADIERE, C.C. BRODER, Y. FENG, P.E. KENNEDY, P.M. MURPHY, E.A. BERGER, "CC CKR5: A Rantes, MBP-lalpha, MIP-1 Beta Receptor as a Fusion Cofactor for Macrophage-tropic HIV-1", SCIENCE, (1996), vol. 272, pages 1955 - 8
    - ALLAWAY G.P., RYDER A.M., BEAUDRY G.A., MADDON P.J., "Synergistic Inhibition of HIV-1 Envelope- Mediated Cell Fusion by CD4-based Molecules in Combination with Antibodies to Gp120 or Gp41", AIDS RES. HUM. RETROVIRUSES, (1993), vol. 9, pages 581 - 7, XP002927935
    - BABA, M., O. NISHIMURA, N. KANZAKI, M. OKAMOTO, H. SAWADA, Y. IIZAWA, M. SHIRAISHI, Y. ARAMAKI, K. OKONOGI, Y. OGAWA, "A Small- molecule, Nonpeptide CCR5 Antagonist with Highly Potent and Selective Anti-hiv-1 Activity", PROC. NATL. ACAD. SCI. USA, (1999), vol. 96, doi:doi:10.1073/pnas.96.10.5698, pages 5698 - 703, XP000890061

DOI:   http://dx.doi.org/10.1073/pnas.96.10.5698
    - BERNARD P., KEZDY KE., VAN MELDEREN L., STEYAERT J., WYNS L., PATO M.L., HIGGINS P.N., COUTURIER M., "The F Plasmid CcdB protein Induces Efficient ATP- dependent Dna Cleavage by Gyrase", J MOL. BIOL., (1993), vol. 23, doi:doi:10.1006/jmbi.1993.1609, pages 534 - 41, XP024008700

DOI:   http://dx.doi.org/10.1006/jmbi.1993.1609
    - BERNARD, P., COUTURIER, M., "Cell Killing by the F Plasmid Ccdb protein Involves Poisoning of DNAtopoisomerase II Complexes", J. MOL. BIO., (1992), vol. 226, doi:doi:10.1016/0022-2836(92)90629-X, pages 735 - 45, XP024015338

DOI:   http://dx.doi.org/10.1016/0022-2836(92)90629-X
    - BLEUL, C.C., M. FARZAN, H. CHOE, C. PAROLIN, I. CLARK-LEWIS, J. SODROSKI, T.A. SPRINGER, "The Lymphocyte Chemoattractant Sdf-1 Is a Ligand for Lestr/fusin and Blocks Hiv-1 Entry", NATURE, (1996), vol. 382, doi:doi:10.1038/382829a0, pages 829 - 33, XP002915916

DOI:   http://dx.doi.org/10.1038/382829a0
    - BRIDGER G.J, SKERLJ R.T., PADMANABHAN S., MARTELLUCCI S.A., HENSON G.W., STRUYF S., WITVROUW M., SCHOLS D., DE CLERCQ E., "Synthesis and Structure-activity Relationships of Phenylenebis(methylene)-linked Bis-azamacrocycles That Inhibit HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor CXCR4", J. MED. CHEM., (1999), vol. 42, doi:doi:10.1021/jm990211i, pages 3971 - 81, XP055113935

DOI:   http://dx.doi.org/10.1021/jm990211i
    - CARPENTER, C.J., COOPER D.A., FISCHL, M.A., GATELL J.M., GAZZARD B.G., HAMMER S.M., HIRSCH M.S., JACOBSEN D.M., KATZENSTEIN D.A.,, "Antiretroviral Therapy in Adults", JAMA, (2000), vol. 283, pages 381 - 89
    - HIV/AIDS Surveillance Report, CDC, (1999), vol. 11
    - COFFIN, J.M., "HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy", SCIENCE, (1995), vol. 267, pages 483 - 489
    - GERDES, K., L.K. POULSEN, T. THISTED, A.K. NIELSON, J. MARTINUSSEN, P.H. ANDREASEN, "The Hok Killer Gene Family in Gram-negative Bacteria", THE NEW BIOLOGIST, (1990), vol. 2, pages 946 - 956, XP009031568
    - HERTOGS, K., M.P. DE BETHUNE, V. MILLER, T. IVENS, P. SCHEL, A. V. CAUWENBERGE, C. VAN DEN EYNDE, V. VAN GERWEN, H. AZIJN, M. VAN, "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Subjects Treated with Antiretroviral Drugs", ANTIMICROB. AGENTS CHEMOTHER, (1998), vol. 42, pages 269 - 276
    - HWANG, J.-J., L. LI, W.F. ANDERSON, "A Conditional Self-inactivating Retrovirus Vector That Uses a Tetracycline-responsive Expression System", J. VIROL., (1997), vol. 71, pages 7128 - 7131
    - JAPOUR, A. J., D. L. MAYERS, V. A. JOHNSON, D. R. KURITZKES, L. A. BECKETT, J. M. ARDUINO, J. LANE, B. R.J., P.S. REICHELDERFER, R, "Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodefiency Virus Type 1 Isolates", ANTIMICROB. AGENTS CHEMOTHER, (1993), vol. 37, pages 1095 - 1101
    - JUDICE J.K., TOM J.Y., HUANG W., WRIN T., VENNARI J., PETROPOULOS C.J., MCDOWELL R.S., "Inhibition HIV Type 1 Infectivity by Constrained Alphahelical Peptides: Implications for the Viral Fusion Mechanism", PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, doi:doi:10.1073/pnas.94.25.13426, pages 13426 - 30, XP002126803

DOI:   http://dx.doi.org/10.1073/pnas.94.25.13426
    - KILBY JM, HOPKINS S, VENETTA TM, DIMASSIMO B, CLOUD GA, LEE JY, ALLDRDGE L, HUNTER E, LAMBERT D, BOLOGNESI D, "Potent Suppression ofHIV-1 I Replication in Humans by T-20, a Peptide Inhibitor of Gp41-mediated Virus Entry", NAT MED., (1998), vol. 4, doi:doi:10.1038/3293, pages 1302 - 7, XP000909990

DOI:   http://dx.doi.org/10.1038/3293
    - MASCOLA, J.R., G. STIEGLER, T.C. VANCOTT, H. KATINGER, C.B. CARPENTER, C.E. HANSON, H. BEARY, D. HAYES, S.S. FRANKEL, D.L. BIRX, "Protection of Macaques Against Vaginal Transmission of a Pathogenic HIV-1/siv Chimeric Virus by Passive Infusion of Neutralizing Antibodies", NATURE MED., (2000), vol. 6, doi:doi:10.1038/72318, pages 207 - 210, XP002615883

DOI:   http://dx.doi.org/10.1038/72318
    - MIYOSHI, H., B. ULRIKE, M. TAKAHASHI, F.H. GAGE, LM. VERMA, "Development of a Self-inactivating Lentivirus Vector", J. VIROL., (1998), vol. 72, pages 8150 - 5157
    - NAVIAUX, R.K., E. COSTANZI, M. HAAS, LM. VERMA, "The Pcl Vector System: Rapid production of Helper-free, High-titer, Recombinant Retroviruses", J. VIROL., (1996), vol. 70, pages 5701 - 5705
    - PETROPOULOS, C.J., N.T. PARKIN, K.L. LIMOLI, Y.S. LIE, T. WRIN, W. HUANG, H. TIAN, D. SMITH, G.A. WINSLOW, D. CAPON, "A Novel Phenotypic Drug Susceptibility Assay for HIV-1", ANTIMICROB. AGENTS & CHEM., (2000), vol. 44, doi:doi:10.1128/AAC.44.4.920-928.2000, pages 920 - 928, XP002962272

DOI:   http://dx.doi.org/10.1128/AAC.44.4.920-928.2000
    - PIKETTY, C., E. RACE, P. CASTIEL, L. BELEC, G. PEYTAVIN, A. SI-MOHAMED, G. GONZALEZ-CANALI, L. WEISS, F. CLAVEL, M. KAZATCHKINE, "Efficacy of a Five-drug Combination Including Ritonavir, Saquinavir and Efavirenz in Subjects Who Failed on a Conventional Triple-drug Regimen: Phenotypic Resistance to protease Inhibitors predicts Outcome of Therapy", AIDS, (1999), vol. 13, pages F71 - F77
    - PORTER, C.C., K.V. LUKACS, G. BOX, Y. TAKEUCHI, M.K.L. COLLINS, "Cationic Liposomes Enhance the Rate of Transduction by a Recombinant Retroviral Vector in Vitro and in Vivo", J. VIROL., (1998), vol. 72, pages 4832 - 4840
    - REIMANN K.A., CATE R.L., WU Y., PALMER L., OLSON D., WAITE B.C., LETVIN N.L., BURKLY L.C., "In Vivo Administration of CD4-specific Monoclonal Antibody: Effect on provirus Load in Rhesus Monkeys Chronically Infected with the Simian Immunodeficiency Virus of Macaques", AIDS RES. HUM. RETROVIRUSES, (1995), vol. 11, pages 517 - 25
    - RICHMAN, D., "Nailing down Another HIV Target", NATURE MED., (1998), vol. 4, pages 1232 - 1233
    - RIMSKY, L.T., D.C. SHUGARS, T.J. MATTHEWS, "Determinants of Human Immunodeficiency Virus Type 1 Resistance to Gp41-derived Inhibitory Peptides", J. VIROL., (1998), vol. 72, pages 986 - 993, XP000909961
    - RODRIGUEZ-ROSADO, R., BRIONES, C., SORIANO, V., "Introduction of HIV Drug-resistance Testing in Clinical Practice", AIDS, (1999), vol. 13, pages 1007 - 1014
    - SCHINAZI, R.F., LARDER, B.A., MELLORS, J.W., "Mutations in Retroviral Genes Associated with Drug Resistance", INTL. ANTIVIRAL NEWS, (1999), vol. 7, pages 46 - 49
    - SHI C., J.W. MELLORS, "A Recombinant Retroviral System for Rapid in Vivo Analysis of Human Immunodefiency Virus Type 1 Susceptibility to Reverse Transcriptase Inhibitors", ANTIMICROB. AGENTS CHEMOTHER, (1997), vol. 41, pages 2781 - 2785, XP002924447
    - STEPHENSON, J., "New Class of Anti-HIV Drugs", JAMA, (1994), vol. 282
    - WILD, C., T. OAK, C. MCDANAL, D. BOLOGNESI, T. MATTHEWS, "A Synthetic Peptide Inhibitor ofHIV Replication: Correlation Between Solution Structure and Viral Inhibition", PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, doi:doi:10.1073/pnas.89.21.10537, pages 10537 - 10541, XP000608915

DOI:   http://dx.doi.org/10.1073/pnas.89.21.10537
    - ZENNOU, V., F. MAMMAMO, S. PAULOUS, D. MATHEZ, F. CALVEL, "Loss of Viral Fitness Associated with Multiple Gag and Gag-pol processing Defects in Human Immunodefiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors in vivo", J. VIROL, (1998), vol. 72, pages 3300 - 06, XP002232098
    - ZIERMANN, R., K. LIMOLI, K. DAS, E. ARNOLD, C.J. PETROPOULOS, N.T. PARKIN, "A Mutation in HIV-1 Protease, N88s, That Causes in Vitro Hypersensitivity to Amprenavir", J. VIROL., (2000), vol. 74, doi:doi:10.1128/JVI.74.9.4414-4419.2000, pages 4414 - 4419, XP002908352

DOI:   http://dx.doi.org/10.1128/JVI.74.9.4414-4419.2000
 US20010874475
 US20020077027
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.